Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran;
Nutrition and Food Security Research Center, andDepartment of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Pediatrics. 2014 Jul;134(1):e176-91. doi: 10.1542/peds.2013-3950.
The efficacy of Saccharomyces boulardii for treatment of childhood diarrhea remains unclear. Our objective was to systematically review data on the effect of S. boulardii on acute childhood diarrhea.
Our data sources included Medline, Embase, CINAHL, Scopus, and The Cochrane Library up to September 2013 without language restrictions. Randomized controlled trials and non-randomized trials that evaluated effectiveness of S. boulardii for treatment of acute diarrhea in children were included. Two reviewers independently evaluated studies for eligibility and quality and extracted the data.
In total, 1248 articles were identified, of which 22 met the inclusion criteria. Pooling data from trials showed that S. boulardii significantly reduced the duration of diarrhea (mean difference [MD], -19.7 hours; 95% confidence interval [CI], -26.05 to -13.34), stool frequency on day 2 (MD, -0.74; 95% CI, -1.38 to -0.10) and day 3 (MD, -1.24; 95% CI, -2.13 to -0.35), the risk for diarrhea on day 3 (risk ratio [RR], 0.41; 95% CI, 0.27 to 0.60) and day 4 (RR, 0.38; 95% CI, 0.24 to 0.59) after intervention compared with control. The studies included in this review were varied in the definition of diarrhea, the termination of diarrhea, inclusion and exclusion criteria, and their methodological quality.
This review and meta-analysis show that S. boulardii is safe and has clear beneficial effects in children who have acute diarrhea. However, additional studies using head-to-head comparisons are needed to define the best dosage of S. boulardii for diarrhea with different causes.
布拉氏酵母菌散治疗儿童腹泻的疗效尚不清楚。我们的目的是系统地回顾布拉氏酵母菌散治疗儿童急性腹泻的疗效数据。
我们的数据来源包括 Medline、Embase、CINAHL、Scopus 和 The Cochrane Library，检索时间截至 2013 年 9 月，无语言限制。纳入评估布拉氏酵母菌散治疗儿童急性腹泻有效性的随机对照试验和非随机对照试验。两位评审员独立评估研究的纳入标准和质量，并提取数据。
共检索到 1248 篇文章，其中 22 篇符合纳入标准。汇总试验数据显示，布拉氏酵母菌散可显著缩短腹泻持续时间（平均差值 [MD]，-19.7 小时；95%置信区间 [CI]，-26.05 至-13.34）、第 2 天粪便频率（MD，-0.74；95%CI，-1.38 至-0.10）和第 3 天粪便频率（MD，-1.24；95%CI，-2.13 至-0.35），降低第 3 天（风险比 [RR]，0.41；95%CI，0.27 至 0.60）和第 4 天（RR，0.38；95%CI，0.24 至 0.59）腹泻的风险，与对照组相比。纳入本综述的研究在腹泻定义、腹泻终止、纳入和排除标准以及方法学质量方面存在差异。
本综述和荟萃分析表明，布拉氏酵母菌散对急性腹泻患儿是安全且有益的。然而，需要更多使用头对头比较的研究来确定不同病因腹泻的最佳布拉氏酵母菌散剂量。
